Clinical Pharmacology & Therapeutics · 1983 · 25 citations · 4 references
PharmacyPharmacokineticsPharmacologyBioavailabilityClinical PharmacologyGeneral PharmacologyDrug DispositionPharmacokinetic Drug InteractionsArea Under The Plasma Concentration-time CurveCombination TherapyPeak Plasma Concentration ChangesPharmacokinetic ParametersSingle-dose AdministrationSteady-state ConcentrationSteady-state Plasma ConcentrationUrinary Recovery Of Drugs
Atenolol kinetics were investigated in six healthy subjects after 100 mg orally, as monotherapy a 6-day treatment began 48 hr later. After a therapy-free interval of 4 wk, the same subjects received the same dose of atenolol with 1 gm ampicillin, 500 mg aspirin, and with 300 mg allopurinol. Allopurinol and aspirin did not substantially alter the kinetics of atenolol. After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy. During long-term treatment with atenolol and ampicillin the bioavailability of atenolol fell to 24% (P less than 0.01). Mean peak plasma levels were lowered from 511 +/- 59 ng/ml on monotherapy to 344 +/- 33 ng/ml after the combination with ampicillin. The area under the plasma level-time curve, mean steady-state concentration, and urinary recovery were reduced, also. Twelve hours after 100 mg atenolol and 1 gm ampicillin, exercise tachycardia was significantly higher than after atenolol alone. During the 4-wk treatment in six hypertensive patients blood pressure levels of those on atenolol alone were not different from those on the combination therapy with ampicillin.
4
Pharmacokinetics of atenolol in relation to renal function
Wilhelm Kirch, H. K�hler, E. Mutschler et al. · European Journal of Clinical Pharmacology · 1981 · 64 citations
Drug production of intestinal malabsorption.